Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

Lambert, Catherine; Dubois, Benedicte; Dive, Dominique; Lysandropoulos, Andreas; Selleslag, Dominik; Vanopdenbosch, Ludo; Van Pesch, Vincent; Vanwijmeersch, Bart; Janssens, Ann

Lambert, Catherine; Dubois, Benedicte; Dive, Dominique; Lysandropoulos, Andreas; Selleslag, Dominik; Vanopdenbosch, Ludo; Van Pesch, Vincent; Vanwijmeersch, Bart; Janssens, Ann.

Afiliação

Lambert C; Department of Hematology, Cliniques Universitaires St Luc, Brussels, Belgium. catherine.lambert@uclouvain.be.
Dubois B; Department of Neurology, Universitaire Zienkenhuis Leuven, Leuven, Belgium.
Dive D; Departement of Neurology, CHU Liège, Esneux, Belgium.
Lysandropoulos A; Neuroimmunology - MS Unit, Neurology Department, CUB- Hôpital Erasme, Brussels, Belgium.
Selleslag D; Department of Hematology, AZ Sint-Jan, Brugge, Belgium.
Vanopdenbosch L; Department of Neurology, AZ Sint Jan, Brugge, Belgium.
Van Pesch V; Department of Neurology, Cliniques Universitaires St Luc, Brussels, Belgium.
Vanwijmeersch B; Departement of Neurology, Rehabilitation and MS Center, Overpelt, Belgium.
Janssens A; Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.

Acta Neurol Belg ; 118(1): 141, 2018 03.

Article em En | MEDLINE | ID: mdl-29500681

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acta Neurol Belg Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google